SciSparc jumps as unit files patent for obesity, fatty liver treatment

Scisparc

12/03/2026 12:05

** Shares of Israel-based drug developer SciSparc SPRC.O surge 34% to $5.21 premarket

** Co says its majority-owned unit NeuroThera Labs filed an international patent for a new combination drug aimed at obesity and metabolic liver disease

** Treatment combines MEAI and PEA, developed with Clearmind Medicine CMND.O, co says

** Targets obesity and MASLD, a condition where excess fat builds up in the liver and disrupts metabolism; MASLD was earlier known as fatty liver disease - SPRC

** Co says therapy could be a safer, cheaper alternative to GLP-1 weight-loss drugs, which can cause side effects

** Shares up ~82% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))